Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

TY - JOUR

T1 - Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies

T2 - a phase 3, randomised, clinical trial and post-hoc efficacy analysis

AU - McNeil, Shelly A.

N1 - Publisher Copyright: © 2019 Elsevier Ltd

PY - 2019/9

Y1 - 2019/9

UR - http://www.scopus.com/inward/record.url?scp=85071373973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071373973&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(19)30163-X

DO - 10.1016/S1473-3099(19)30163-X

M3 - Article

C2 - 31399377

AN - SCOPUS:85071373973

SN - 1473-3099

VL - 19

SP - 988

EP - 1000

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 9

ER -